HIV, syphilis, and hepatitis B virus infection and male circumcision in five Sub-Saharan African countries: Findings from the Population-based HIV Impact Assessment surveys, 2015-2019.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2023
Historique:
received: 21 03 2023
accepted: 06 08 2023
medline: 18 9 2023
pubmed: 18 9 2023
entrez: 18 9 2023
Statut: epublish

Résumé

Voluntary medical male circumcision (VMMC) has primarily been promoted for HIV prevention. Evidence also supports that male circumcision offers protection against other sexually transmitted infections. This analysis assessed the effect of circumcision on syphilis, hepatitis B virus (HBV) infection and HIV. Data from the 2015 to 2019 Population-based HIV Impact Assessments (PHIAs) surveys from Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe were used for the analysis. The PHIA surveys are cross-sectional, nationally representative household surveys that include biomarking testing for HIV, syphilis and HBV infection. This is a secondary data analysis using publicly available PHIA data. Univariate and multivariable logistic regression models were created using pooled PHIA data across the five countries to assess the effect of male circumcision on HIV, active and ever syphilis, and HBV infection among sexually active males aged 15-59 years. Circumcised men had lower odds of syphilis infection, ever or active infection, and HIV, compared to uncircumcised men, after adjusting for covariates (active syphilis infection = 0.67 adjusted odds ratio (aOR), 95% confidence interval (CI), 0.52-0.87, ever having had a syphilis infection = 0.85 aOR, 95% CI, 0.73-0.98, and HIV = 0.53 aOR, 95% CI, 0.47-0.61). No difference between circumcised and uncircumcised men was identified for HBV infection (P = 0.75). Circumcised men have a reduced likelihood for syphilis and HIV compared to uncircumcised men. However, we found no statistically significant difference between circumcised and uncircumcised men for HBV infection.

Identifiants

pubmed: 37721926
doi: 10.1371/journal.pgph.0002326
pii: PGPH-D-23-00457
pmc: PMC10506706
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0002326

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1139-1148
pubmed: 33972367
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
PLoS Med. 2011 Nov;8(11):e1001132
pubmed: 22140367
BMC Public Health. 2021 Apr 6;21(1):656
pubmed: 33823828
Clin Liver Dis. 2016 Nov;20(4):607-628
pubmed: 27742003
Lancet Glob Health. 2017 Nov;5(11):e1113-e1122
pubmed: 29025633
Clin Infect Dis. 2017 Aug 01;65(3):389-395
pubmed: 28419198
J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25355
pubmed: 31468737
J Int AIDS Soc. 2013 Jun 06;16:18500
pubmed: 23746302
Am J Public Health. 1994 Feb;84(2):197-201
pubmed: 8296939
PLoS One. 2011;6(11):e27561
pubmed: 22140449
AIDS. 2009 Oct 23;23(16):2209-13
pubmed: 19770623
PLoS One. 2010 Dec 16;5(12):e15552
pubmed: 21179493
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
J Virol Methods. 1987 Aug;17(1-2):69-79
pubmed: 3312269
BMJ Glob Health. 2019 May 30;4(3):e001389
pubmed: 31263584
Bull World Health Organ. 2020 May 01;98(5):315-329
pubmed: 32514197
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Sex Health. 2015 Apr;12(2):96-102
pubmed: 25514173
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Epidemiology. 2004 Mar;15(2):157-63
pubmed: 15127907
Sex Transm Infect. 1998 Oct;74(5):368-73
pubmed: 10195035
PLoS One. 2017 May 12;12(5):e0177076
pubmed: 28498835

Auteurs

Megan E Peck (ME)

Division of Global HIV & TB, HIV Prevention Branch, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, United States of America.

Megan Bronson (M)

Division of Global HIV & TB, Epidemiology and Surveillance Branch, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, United States of America.

Gaston Djomand (G)

Division of Global HIV & TB, HIV Prevention Branch, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, United States of America.

Ikuzo Basile (I)

Ministry of Health, Rwanda Biomedical Center, Kigali City, Rwanda.

Kamanzi Collins (K)

ICAP at Columbia University, Kigali City, Rwanda.

Ida Kankindi (I)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Kigali, Rwanda.

Eugenie Kayirangwa (E)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Kigali, Rwanda.

Samuel S Malamba (SS)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Kigali, Rwanda.

Veronicah Mugisha (V)

ICAP at Columbia University, Kigali City, Rwanda.

Sabin Nsanzimana (S)

Ministry of Health, Rwanda Biomedical Center, Kigali City, Rwanda.

Eric Remera (E)

Ministry of Health, Rwanda Biomedical Center, Kigali City, Rwanda.

Kokuhumbya J Kazaura (KJ)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Dar-es-Salaam, Tanzania.

Mbaraka Amuri (M)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Dar-es-Salaam, Tanzania.

Susan Mmbando (S)

National AIDS Control Program, Ministry of Health, Dar-es-Salaam, Tanzania.

George S Mgomella (GS)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Dar-es-Salaam, Tanzania.

Daimon Simbeye (D)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Dar-es-Salaam, Tanzania.

Anna Colletar Awor (A)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Kampala, Uganda.

Samuel Biraro (S)

Columbia University, Kampala, Uganda.

Geoffrey Kabuye (G)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Kampala, Uganda.

Wilford Kirungi (W)

Ministry of Health, Kampala, Uganda.

Omega Chituwo (O)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.

Brave Hanunka (B)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.

Royd Kamboyi (R)

Department of Public Health, Ministry of Health, Lusaka, Zambia.

Lloyd Mulenga (L)

Department of Public Health, Ministry of Health, Lusaka, Zambia.

Bupe Musonda (B)

Department of Public Health, Ministry of Health, Lusaka, Zambia.

Brian Muyunda (B)

Division of Global HIV & TB, Centers for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.

Tepa Nkumbula (T)

ICAP at Columbia University, Lusaka, Zambia.

Rickie Malaba (R)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.

John Mandisarisa (J)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.

Godfrey Musuka (G)

ICAP at Columbia University, Harare, Zimbabwe.

Amy E Peterson (AE)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.

Carlos Toledo (C)

Division of Global HIV & TB, HIV Prevention Branch, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, United States of America.

Classifications MeSH